Press Release |
Cobalis Corp. (CLSC) Launches Patented Revolutionary Allergy Prevention Product PreHistin(R) for Worldwide Sales at
* Reuters is not responsible for the content in this press release.
LAGUNA BEACH, CA, May 08 (MARKET WIRE) -- Cobalis Corp. (PINKSHEETS: CLSC), a pharmaceutical biotech company specializing in the development of anti-allergy medications, announced today that their patented revolutionary allergy prevention product PreHistin(R) is now available for worldwide commercial sales and orders at www.prehistin.com. During multiple clinical trials conducted by Cobalis Corp., pre-seasonal treatment with PreHistin(R) was shown to reduce and regulate IgE levels and their resultant histamine production in both allergy and non-allergy sufferers. Cobalis Corp. has conducted numerous clinical trials in over 30 board certified clinics throughout the U.S. with over 2,200 patients in the Phase III trials of PreHistin(R). As a result, the data from the clinical trials enables Cobalis to launch patented PreHistin(R) as a nutraceutical supplement with clinical claims. Dr. Paul Ratner, the lead clinical investigator during Cobalis trials of PreHistin(R) and a Board Certified Allergist, as well as a Fellow of the American Academy of Allergy and Immunology, said, "Results were dramatic. PreHistin(R) was safe, showed no side effects and was non-drowsy. PreHistin(R) is a novel therapy that can be taken preventatively and works extremely well." PreHistin(R) is being manufactured by Monarch Nutraceutical, a division of Nutraceutical Corp. in Ogden, Utah. Nutraceutical Corp. (NUTR) was the original manufacturer of PreHistin(R) under the name Alleratin, which was distributed to thousands of allergy suffers without cost for compassionate use. Chas Radovich, the President of Cobalis, stated, "We are extremely proud to have reached this milestone turning Cobalis from a research corporation to a commercially viable company with the launch of PreHistin(R) for immediate domestic and international sales to the public at www.prehistin.com. Worldwide fulfillment of customer orders for our initial internet marketing campaign for PreHistin will commence next week. PreHistin(R) is a patented product, safe for long-term daily use and available without a prescription. PreHistin(R) is a cherry flavored, all natural, proprietary cyanocobalamin (vitamin B12) sub-lingual lozenge that is taken twice daily to regulate allergy sufferers' response to both indoor and outdoor allergens with daily and year round usage." Cyanocobalamin has an excellent safety record, is safety accepted by the US FDA, and has no upper dosage limits or contra-drug indications. For over 50 years the FDA has approved cyanocobalamin as a drug for anemia. Each PreHistin(R) lozenge contains 3.3mg Cyanocobalamin. For less than $1.00 per day, twice daily use of PreHistin has been clinically shown to significantly increase serum vitamin B12 levels, making PreHistin(R) a cost effective and convenient alternative to other Vitamin B12 therapies. Mr. Radovich continued, "After many years of research, we are finally able to make PreHistin(R) available to the over 55,000,000 allergy sufferers in the United States, many of whom have been waiting for an all natural and preventive alternative to their allergy problems. Immediate commencement of sales through www.PreHistin.com marks the beginning of our domestic and international distribution sales partnerships and channels for PreHistin(R)." ABOUT COBALIS CORP. -- PREHISTIN(R) Headquarter in Laguna Beach, California, Cobalis Corp. is an over the counter pharmaceutical company. Its flagship product, PreHistin(R) is designed to prevent the primary causes of airborne allergies. The anti allergy market is projected to be over fifteen billion dollars by 2010, and PreHistin(R) is in the unique position of being the only Phase III clinically tested sublingual product with outstanding test results and is poised to get its share of the market. PreHistin, "the world's first pre-histamine," has shown in previous studies to modulate the body's level of protein IgE, reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Prior studies have shown that the active ingredient in PreHistin has essentially no risks or adverse effects to the general population including sedation drowsiness found in most of the allergy products now available. For company info please visit our website at www.Cobalis.com. For product info and ordering please visit at www.prehistin.com. Contact: Cobalis Corp. Email Contact Copyright 2009, Market Wire, All rights reserved. -0-